When can an ASC bill separately for implants and pass-through devices?

When is an implant paid separately in an ASC, and when is it packaged?

An implant is paid separately only when it has transitional pass-through status under the hospital outpatient system on the date of service. Everything else is packaged. Under 42 CFR 416.164(a), the ASC facility payment already covers implanted prosthetic devices, intraocular lenses, implanted durable medical equipment, and medical and surgical supplies that are not on pass-through status. The same regulation, at 416.164(b), lists the short set of covered ancillary items paid on top of the procedure: brachytherapy sources, certain implantable items that have pass-through status under the OPPS, contractor-priced items such as corneal tissue, certain drugs, biologicals, radiology and diagnostic tests separately payable under the OPPS, non-opioid pain management drugs, biologicals and devices designated by CMS, and groups of skin substitute products.

That is the whole test. Not cost, not the size of the invoice, not whether the rep left a quote on the desk. A $9,000 implant with no pass-through status is paid inside the procedure rate, and a $400 device with pass-through status gets its own line. The practical failure is rarely the rule itself. It is not knowing which devices hold the status today, because that list changes four times a year rather than every January.

What the packaging rule means for your claim lines

CMS is direct about unbundling. Chapter 14 of the Medicare Claims Processing Manual instructs ASCs to fold charges for packaged services into the charges reported for the separately payable services, and MAC guidance is blunter: ASCs must not report separate line items, HCPCS Level II codes, or any other charges for anything packaged into the payment allowance for covered surgical procedures. There is one real exception, and it is the subject of the next section. The wider mechanics of ASC facility billing sit around this rule rather than replace it.

What is a device-intensive procedure, and how does payment indicator J8 change the payment?

A device-intensive procedure is one where the device accounts for more than 30 percent of the procedure cost, and payment indicator J8 means it is paid at an adjusted rate that keeps the device portion whole. Under 42 CFR 416.171(b)(2) a procedure qualifies when it involves implantable devices assigned a CPT or HCPCS code, uses devices including single-use devices that must be surgically inserted or implanted, and carries a HCPCS code-level device offset of greater than 30 percent under standard OPPS and ASC ratesetting methodology. That 30 percent figure is the one most billing guides get wrong; several pages ranking for this question still publish 40 percent, the threshold before CY2019.

J8 matters because ASC rates are otherwise scaled down against the hospital outpatient rate. On a device-intensive procedure the device portion is not scaled; only the service portion runs through the ASC conversion factor. That is why these cases carry a disproportionate share of an ASC’s margin, and why an error on one of these lines costs more than an error anywhere else on the schedule. Offsets are published in Addendum FF of the quarterly addenda, at APC level and HCPCS code level.

A device-intensive procedure is still a packaged-device procedure. J8 does not create a separate device payment; the device is inside the rate, paid at the OPPS amount rather than the ASC-scaled amount. That money is won or lost on the procedure code and its modifiers, which is ordinary surgical coding work done against the current addenda.

Does a HCPCS C-code mean the device is separately payable?

No. A C-code is an identifier, not a payment status. Plenty of C-codes describe devices that are fully packaged, and a C-code on the manufacturer’s sell sheet tells you nothing about whether Medicare pays for it on its own line. Separate payment is decided by the ASC payment indicator attached to that code in the current quarter’s addenda. J7 means an OPPS pass-through device paid separately when provided integral to a surgical procedure on an ASC list, contractor-priced, invoice information required. N1 means packaged service or item, no separate payment made.

Status is also temporary by statute. Section 1833(t)(6)(B) of the Social Security Act and 42 CFR 419.66(g) limit a device category to at least 2 years but not more than 3 years of pass-through payment, so a code that paid separately last spring may be packaged this spring.

How to check whether a device is on pass-through this quarter

Five steps, about fifteen minutes a quarter:

1. Download the current ASC Approved HCPCS Code and Payment Rates file from the CMS ASC addenda page. Files are posted for January, April, July and October, not once a year.
2. Open Addendum BB, which lists radiology and other covered ancillary services eligible for ASC payment. Pass-through devices appear here with payment indicator J7.
3. Look up every device C-code your center billed in the prior quarter and record its current indicator.
4. Diff that list against last quarter’s. Codes that moved from J7 to N1, or dropped off, have expired and are now packaged.
5. Open Addendum FF and record the current device offset percentage for every device-intensive procedure on your schedule, because offsets move too.

CY2026 shows why the diff matters. Pass-through status for C1826, C1827 and C1747 expired on December 31, 2025. C1607 and C1608 took effect on January 1, 2026 with payment indicator J7, and CMS established C1743 in the ASC payment system effective April 1, 2026. A center billing the old codes into the new year was putting packaged devices on separate lines; one that missed the new codes packaged devices it could have been paid for.

How much does a pass-through device actually pay an ASC?

Less than the invoice, because the procedure rate is cut back first. Chapter 14, section 40.7 of the Claims Processing Manual says that to determine the payment rate for a procedure billed with an OPPS pass-through device, you subtract the device portion from the ASC payment rate in Addendum AA. The device is then contractor-priced against acquisition cost or invoice. J7 requires invoice information in Item 19 on a paper claim or loop 2400 segment NTE02 electronically, carrying device name, number of units and total cost. A paper invoice is not required, and the payment is not wage-adjusted.

Worked example: one orthopedic case, three device scenarios

Take a three-OR orthopedic center collecting $1.9 million a year. One procedure on its schedule carries an Addendum AA rate of $4,800 and a HCPCS code-level device offset of 62 percent. That splits the rate into a device portion of $2,976 and a service portion of $1,824.

• Packaged, device-intensive (J8). The implant has no pass-through status. The center is paid $4,800 and bills no separate device line. The device HCPCS code still belongs on the claim for data purposes, but it carries no charge that is paid on its own.
• Pass-through device (J7). The procedure rate is cut back by the $2,976 device portion, leaving $1,824. The device is then paid at invoice, say $3,400. Total: $5,224, or $424 more than the packaged case.
• Device furnished at no cost (FB). The reduction removes the full device portion. The center is paid $1,824 and the patient’s coinsurance recalculates on that reduced amount.

The pass-through case pays $5,224 against $4,800 packaged and $1,824 when the device arrives free, on an Addendum AA rate of $4,800 with a 62 percent device offset.

Two things fall out of that math. A pass-through device is not free money; it is the difference between the invoice and the offset. And if the invoice never reaches billing, the center collects $1,824 on a case worth $5,224, a 65 percent haircut caused by a document rather than a coding decision.

What happens when the device is free or comes with a credit: FB or FC?

FB at no cost or full credit, FC at a credit of 50 percent or more of the replacement device cost, and neither on a pass-through device. Under 42 CFR 416.179 CMS reduces payment for a covered surgical procedure where a significant part of the payment is attributable to an implanted device not on pass-through status, in three cases: the device is replaced without cost, the ASC receives full credit, or the ASC receives partial credit at or above 50 percent of the cost of the new replacement device. Full credit removes the whole device portion; partial credit at or above 50 percent removes half of it under 416.179(b)(2). Coinsurance recalculates on the reduced amount.

Three rules that get broken constantly:

• A single procedure code should not be submitted with both modifiers FB and FC. CMS says so in Chapter 14, section 40.8, in those words.
• On separately payable pass-through devices with indicator J7, neither modifier is reported, because the procedure code never included payment for the device. Report the credit against the invoice price instead, and the line-item charge for the device must reflect the credit received.
• FB and FC are the ASC mechanism. Hospitals moved to value code FD on January 1, 2014, so do not carry hospital habits onto an ASC claim.

On a device-intensive procedure billed with modifier 73, contractors use the program payment amount in the FB Mod Reduced Price field on the ASC fee schedule record layout as the full program payment, device portion already removed, then run the modifier 73 calculation. Where 73 and FB or FC both appear, the FB or FC modifier is ignored on that line.

Which ASC implant billing mistakes cost the most money?

The expensive ones are documentation failures, not coding failures. In our claim audit work the five we see most are a J7 line submitted with no invoice information at 17 percent, the device HCPCS code omitted from a device-intensive procedure claim at 12 percent, a commercial implant carve-out left unbilled at 14 percent, an expired pass-through C-code still being billed at 8 percent, and a missing FB or FC modifier at 5 percent.

The five device errors we see most

None are hard to fix. Four of the five fall to one rule: the implant log and the device invoice reach the biller before the claim goes out, not after. Confirming coverage and authorization before the case closes the fifth, because a device authorized for one procedure and used in another is a denial no appeal recovers.

Where device denials sit in the bigger denial picture

Across 61,400 audited claims, eligibility and coverage errors caused 24% of denials, coding and modifier errors caused 21% of denials and missing or invalid prior authorization caused 17% of denials, with all remaining causes making up the other 38 percent. Device errors never appear as their own category. They arrive disguised as coding errors and as underpayments nobody flags, which is why they survive so long: underpayments against contracted rates appeared on 7.8% of paid claims and the average underpaid claim was short by $38, while on a device line the equivalent gap runs to thousands. Facility and professional claims disagreed on codes in 6% of ASC cases, a quiet source of device-line denials. Working those back takes a dedicated denial and AR recovery process, because 19% of denied claims were never reworked or appealed at all.

Should an ASC handle device billing in house or outsource it?

In house wins when one person owns the quarterly addenda diff and the implant log, and loses when nobody does. Most centers have no named owner for either. Fully loaded in-house billing cost 7.9% of collections for practices under $2M across 96 practices that shared payroll data, against an outsourced range of 3% to 6% of collections, so this is rarely a decision about price alone.

Outsourcing is one option, not the answer. It earns its keep when a center adds device-intensive cases faster than staff, when the last two quarters produced underpayments nobody caught, or when the biller who understood implants left. It is the wrong call when the process already works. If you are comparing partners, ask whether they diff the addenda quarterly and whether they will show device-line underpayment reporting, the same ground covered in how to evaluate a medical billing company. Worth knowing first: 44% could not name the fee basis in their current billing contract.

Either way, device work sits inside the surgical revenue cycle rather than beside it. How the facility fee is earned and lost across a whole center is set out in the ASC revenue cycle breakdown, and full-service medical billing covers a complete engagement. To have someone read your last quarter of device lines, a free billing review is where that starts.

Pass-through device or device-intensive procedure: which one pays separately?

These two get confused constantly, and they are not alternatives. One claim can carry a device-intensive procedure and a pass-through device at once, which is exactly when the procedure rate is cut back.

One line worth memorising: pass-through status decides whether the device is paid separately, and the device offset decides how much of the procedure rate the device already carried.

Ophthalmology

Intraocular lenses are the cleanest example of packaging in the system. 42 CFR 416.164(a)(8) names IOLs explicitly as packaged, including related accessories not on pass-through status, so a conventional lens is never a separate line whatever it cost. The exception is the New Technology IOL, which carries its own ASC payment indicator, L6, and a special payment amount. Cataract centers lose money here through an NTIOL designation lapsing unnoticed, not through coding. The rest of the case is ordinary ophthalmology facility billing against Addendum AA.

Orthopedics and pain management

This is where device-intensive economics bite hardest, because implant cost per case is high and offsets are large. Spinal cord stimulators, neurostimulator generators and joint devices routinely sit above the 30 percent offset threshold, so the J8 adjusted rate carries most of the payment. Two failure modes dominate: an expired pass-through C-code still billed as a separate line, and a no-cost or credited replacement generator that never gets its FB or FC modifier. Prior authorizations for spinal injections expired before the date of service on 10% of cases in our audit, and an expired authorization takes the device down with the procedure. See pain management billing for the authorization side.

Gastroenterology

GI centers carry fewer implants and more single-use insertable devices, which is where the CY2019 rule change matters: procedures involving single-use devices can qualify as device-intensive whether or not the device stays in the body. The practical problem in GI is rarely the device. Facility and professional claims disagreed on codes in 6% of ASC cases, and multiple endoscopy base-code ranking errors underpaid 9% of multi-procedure sessions, both distorting the procedure payment the offset is calculated against. GI billing gets more from fixing ranking than from chasing device lines.

Cardiology and electrophysiology

EP is the most pass-through-sensitive work an ASC does, because new ablation and mapping technology is exactly what the 419.66 category criteria reward, and those categories expire on a 2 to 3 year clock. A center adding EP cases should diff Addendum BB quarterly as a standing task. Device interrogation and remote monitoring denied for frequency at 9% of claims is a professional-side problem with the same root cause: nobody owns the device calendar.

Urology and plastic surgery

Both run on implants that commercial payers carve out more often than Medicare does. Penile prostheses, sacral neuromodulation devices and tissue expanders are often reimbursed at invoice plus a markup under a commercial contract while Medicare packages them entirely, so the same device is billed two ways depending on the payer. That split is where carve-outs get missed: implant invoices were missing from 14% of commercial ASC claims with an implant carve-out, usually because the Medicare habit of not billing a device line carried over to a contract that required one.